Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the Dow Jones Industrial Average DJIA rising 0.

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall sharply from a year earlier.

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly's outlook for sales of its blockbuster ... following the December report on producer prices. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were down less than 0.5%.

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast ...

though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added ...

World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence the pace of the Federal Reserve’s rate cuts

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the market needs?

U.S. stock futures are pointing higher ahead of a closely watched inflation report; JPMorgan Chase shares are moving higher after fourth-quarter results were better than analysts'

US stocks gave up early gains to end mixed. Investors await key consumer inflation data and the start of earnings season on Wednesday.

Asian shares are mixed after gains for oil and gas producers helped offset drops for Nvidia and other Big Tech companies on Wall Street.